Lymphoma Clinical Trials

Yes. Hodgkin lymphoma and non-Hodgkin lymphoma are biologically distinct diseases with different treatment approaches, so they have separate clinical trials. Non-Hodgkin lymphoma trials are further divided by subtype, such as diffuse large B-cell lymphoma or follicular lymphoma. Your specific subtype determines which trials you are eligible for.

Yes. Some trials focus specifically on patients in remission, studying maintenance therapies or monitoring strategies designed to prevent relapse. There are also survivorship trials that address long-term side effects of treatment. Ask your oncologist about trials that match your current disease status.

It is extremely rare for a lymphoma trial to have a placebo-only group. Most trials compare the new treatment plus standard therapy against standard therapy alone, or compare two active treatments. You will always know before enrolling whether the trial includes a placebo component.

Many trials require a fresh biopsy, especially if your most recent one is older than a few months or if you have received treatment since your last biopsy. This is because lymphoma biology can change over time or after treatment. The biopsy helps confirm your subtype and test for biomarkers that determine trial eligibility.

Many academic cancer centers offer virtual pre-screening consultations to determine if you might qualify before you travel. Some trials allow portions of treatment and monitoring to be done at a local oncologist through satellite site arrangements. Ask the trial coordinator about remote participation options and travel reimbursement programs.